Fig 1.
Consolidated standards for reporting of trials diagram.
Fig 2.
MicronJet600 compared to the 27 G hypodermic needle (A), and MicronJet600 placed on 1 mL syringe (B).
Fig 3.
General study scheme.
Table 1.
Baseline demographic characteristics.
Fig 4.
Mean estimates of VAS scores with corresponding 95% confidence intervals for pain experienced by the subjects after cannulations preceded by the lidocaine injection (MJ-Lido vs MJ-Saline and MJ-Lido vs No pretreatment groups (red bar), saline injection (MJ-Lido vs MJ-Saline group, green bar), or performed without any pretreatment (MJ-Lido vs No pretreatment group, blue bar).
Fig 5.
The bar chart shows the distribution of subjects between the groups ranked by VAS-score for the cases of the injection of 100 μL of 2% lidocaine or placebo prior to cannulation, or cannulation without any pretreatment.
Thus, the non-shaded bar, slightly shaded bar, moderately shaded bar and entirely shaded red bar represents the percentage of subjects related to the groups: VAS-score = 0, VAS-score≤10, VAS-score≤20, VAS-score>20, respectively.
Fig 6.
The multi-line chart demonstrates mean estimates of VAS scores with 95% confidence intervals for pain experienced by subjects due to the superficial pin-pricks with 27 G needle for three different time points at 15, 30 and 45 minutes after the lidocaine injection with MicronJet600, and at 1, 2 and 3 centimeters from the injection site.
Table 2.
Mean estimates with corresponding 95% confidence intervals for VAS pain score due to pin-pricks with a 27G needle at three time points at 15, 30 and 45 minutes after the lidocaine injection with MicronJet600, and distances at 1, 2 and 3 centimeters from the injection site.